GHENT, Belgium, May 13, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] announces that it will be presenting at the 2014 UBS Global Life Sciences Conference, which is taking place from 19 till 21 May 2014 at the Sheraton New York Hotel, New York.
The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO of Ablynx, on Monday 19 May at 09:00 a.m. EST / 03:00 p.m. CET, and will provide an update on the Company's late-stage proprietary Nanobody® programmes, its growth and partnering strategy and the outlook for the near term future.
The presentation will be webcast live and can be accessed on the day via this link or via the Ablynx website at www.ablynx.com. A replay of the webcast will be available on the Company's website for 30 days following the presentation. To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 30 programmes in the pipeline and seven Nanobodies in clinical development. Ablynx has on-going research collaborations and significant partnerships with companies including AbbVie, Boehringer Ingelheim, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com.
For more information, please contact
Dr Edwin Moses
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
Follow us on Twitter @AblynxABLX
Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 203 709 5700
pdf version of the press release http://hugin.info/137912/R/1785095/611937.pdf